Neovacs S.A. (ALNEV.PA)
EUR 1.11
(-11.15%)
EUR 1.11
(-11.15%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -8.74 Million EUR | -146.4% |
| 2022 | -3.54 Million EUR | 70.02% |
| 2021 | -11.83 Million EUR | -92.71% |
| 2020 | -6.14 Million EUR | 18.62% |
| 2019 | -7.54 Million EUR | 29.98% |
| 2018 | -10.78 Million EUR | 27.35% |
| 2017 | -14.83 Million EUR | -6.5% |
| 2016 | -13.93 Million EUR | -197.53% |
| 2015 | -4.68 Million EUR | 37.67% |
| 2014 | -7.51 Million EUR | -9.36% |
| 2013 | -6.86 Million EUR | 3.92% |
| 2012 | -7.15 Million EUR | 11.88% |
| 2011 | -8.11 Million EUR | 9.68% |
| 2010 | -8.98 Million EUR | -30.37% |
| 2009 | -6.89 Million EUR | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q2 | -30.99 Million EUR | 0.0% |
| 2023 Q2 | -4.28 Million EUR | 0.0% |
| 2023 FY | -8.74 Million EUR | -146.4% |
| 2023 Q4 | -4.46 Million EUR | 0.0% |
| 2022 Q2 | -2.83 Million EUR | 0.0% |
| 2022 Q4 | -714.18 Thousand EUR | 0.0% |
| 2022 FY | -3.54 Million EUR | 70.02% |
| 2021 FY | -11.83 Million EUR | -92.71% |
| 2021 Q2 | -3.17 Million EUR | 0.0% |
| 2021 Q4 | -8.66 Million EUR | 0.0% |
| 2020 Q2 | -6.43 Million EUR | 0.0% |
| 2020 Q4 | 295.7 Thousand EUR | 0.0% |
| 2020 FY | -6.14 Million EUR | 18.62% |
| 2019 Q2 | -3.75 Million EUR | 0.0% |
| 2019 Q4 | -3.79 Million EUR | 0.0% |
| 2019 FY | -7.54 Million EUR | 29.98% |
| 2018 FY | -10.78 Million EUR | 27.35% |
| 2018 Q4 | -4.68 Million EUR | 0.0% |
| 2018 Q2 | -6.09 Million EUR | 0.0% |
| 2017 Q2 | -8.12 Million EUR | 0.0% |
| 2017 FY | -14.83 Million EUR | -6.5% |
| 2017 Q4 | -6.71 Million EUR | 0.0% |
| 2016 Q2 | -6.77 Million EUR | 0.0% |
| 2016 FY | -13.93 Million EUR | -197.53% |
| 2016 Q4 | -7.15 Million EUR | 0.0% |
| 2015 FY | -4.68 Million EUR | 37.67% |
| 2015 Q4 | 186.95 Thousand EUR | 0.0% |
| 2015 Q2 | -4.86 Million EUR | 0.0% |
| 2014 Q2 | -3.86 Million EUR | 0.0% |
| 2014 Q4 | -3.65 Million EUR | 0.0% |
| 2014 FY | -7.51 Million EUR | -9.36% |
| 2013 Q2 | -3.27 Million EUR | -90.67% |
| 2013 Q1 | -1.71 Million EUR | 0.0% |
| 2013 FY | -6.86 Million EUR | 3.92% |
| 2013 Q4 | -3.59 Million EUR | -108.74% |
| 2013 Q3 | -1.71 Million EUR | 47.55% |
| 2012 Q1 | -1.78 Million EUR | 0.0% |
| 2012 Q4 | -1.71 Million EUR | 3.58% |
| 2012 Q3 | -1.78 Million EUR | 0.0% |
| 2012 FY | -7.15 Million EUR | 11.88% |
| 2012 Q2 | -1.78 Million EUR | 0.0% |
| 2011 Q2 | -2.82 Million EUR | 0.0% |
| 2011 Q3 | -2.82 Million EUR | 0.0% |
| 2011 Q4 | -1.78 Million EUR | 36.89% |
| 2011 FY | -8.11 Million EUR | 9.68% |
| 2011 Q1 | -2.82 Million EUR | 0.0% |
| 2010 Q2 | -2.24 Million EUR | 0.0% |
| 2010 Q3 | -2.24 Million EUR | 0.0% |
| 2010 Q4 | -2.82 Million EUR | -25.86% |
| 2010 Q1 | -2.24 Million EUR | 0.0% |
| 2010 FY | -8.98 Million EUR | -30.37% |
| 2009 Q3 | -1.72 Million EUR | 0.0% |
| 2009 Q1 | -1.72 Million EUR | 0.0% |
| 2009 FY | -6.89 Million EUR | 0.0% |
| 2009 Q2 | -1.72 Million EUR | 0.0% |
| 2009 Q4 | -2.24 Million EUR | -30.37% |
| 2008 Q4 | -1.72 Million EUR | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| ABIONYX Pharma SA | -3.51 Million EUR | -148.535% |
| ABIVAX Société Anonyme | -147.74 Million EUR | 94.082% |
| Adocia SA | -21.16 Million EUR | 58.683% |
| Aelis Farma SA | -5.07 Million EUR | -72.183% |
| Biophytis S.A. | -17.02 Million EUR | 48.646% |
| Advicenne S.A. | -7.03 Million EUR | -24.356% |
| genOway Société anonyme | 1.56 Million EUR | 657.769% |
| IntegraGen SA | -171.39 Thousand EUR | -5001.226% |
| Medesis Pharma S.A. | -3.95 Million EUR | -120.823% |
| NFL Biosciences SA | -3.74 Million EUR | -133.44% |
| Plant Advanced Technologies SA | 79.16 Thousand EUR | 11144.032% |
| Quantum Genomics Société Anonyme | -3.17 Million EUR | -175.736% |
| Sensorion SA | -22.06 Million EUR | 60.371% |
| Theranexus Société Anonyme | -6.82 Million EUR | -28.054% |
| TME Pharma N.V. | -6.73 Million EUR | -29.802% |
| Valbiotis SA | -7.36 Million EUR | -18.668% |
| TheraVet SA | -1.57 Million EUR | -456.657% |
| Valerio Therapeutics Société anonyme | -20.34 Million EUR | 57.022% |
| argenx SE | -272.91 Million EUR | 96.796% |
| BioSenic S.A. | -28.77 Million EUR | 69.618% |
| Celyad Oncology SA | -8.44 Million EUR | -3.497% |
| DBV Technologies S.A. | -67.26 Million EUR | 87.002% |
| Galapagos NV | 211.69 Million EUR | 104.13% |
| Genfit S.A. | -28.89 Million EUR | 69.74% |
| GeNeuro SA | -14.75 Million EUR | 40.75% |
| Hyloris Pharmaceuticals SA | -15.38 Million EUR | 43.151% |
| Innate Pharma S.A. | -7.57 Million EUR | -15.501% |
| Inventiva S.A. | -110.42 Million EUR | 92.082% |
| MaaT Pharma SA | -19.71 Million EUR | 55.655% |
| MedinCell S.A. | -25.03 Million EUR | 65.079% |
| Nanobiotix S.A. | -39.7 Million EUR | 77.976% |
| Onward Medical N.V. | -36.18 Million EUR | 75.834% |
| Oryzon Genomics S.A. | -3.35 Million EUR | -160.769% |
| OSE Immunotherapeutics SA | -23 Million EUR | 61.99% |
| Oxurion NV | -18.96 Million EUR | 53.907% |
| Pharming Group N.V. | -9.75 Million EUR | 10.384% |
| Poxel S.A. | -35.09 Million EUR | 75.083% |
| GenSight Biologics S.A. | -26.22 Million EUR | 66.654% |
| Transgene SA | -22.32 Million EUR | 60.841% |
| Financière de Tubize SA | 88.15 Million EUR | 109.919% |
| UCB SA | 343 Million EUR | 102.549% |
| Valneva SE | -101.42 Million EUR | 91.38% |
| Vivoryon Therapeutics N.V. | -28.34 Million EUR | 69.15% |